[1] Arroyo V, Angeli P, Moreau R, et al. The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis[J]. J Hepatol,2021,74(3):670-685.
[2] Gustot T, Stadlbauer V, Laleman W, et al. Transition to decompensation and acute-on-chronic liver failure: role of predisposing factors and precipitating events[J]. J Hepatol,2021,75(Suppl1):S36-S48.
[3] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno Ⅶ - Renewing consensus in portal hypertension[J]. J Hepatol,2022,76(4):959-974.
[4] Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J]. Gastroenterology,2013,144(7):1426-1437,1437.e1-e9.
[5] Villanueva C, Albillos A, Genescà J, et al. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis[J]. J Hepatol,2021,75(3):589-599.
[6] D'Amico G, Bernardi M, Angeli P. Towards a new definition of decompensated cirrhosis[J]. J Hepatol,2022,76(1):202-207.
[7] 林勇,曾欣,胡平方.中国肝硬化临床诊治共识意见[J].临床肝胆病杂志,2023,39(09):2057-2073.
[8] Kumar R, Kumar S, Prakash S S. Compensated liver cirrhosis: natural course and disease-modifying strategies[J]. World J Methodol,2023,13(4):179-193.
[9] Trebicka J, Fernandez J, Papp M, et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology[J]. J Hepatol,2020,73(4):842-854.
[10] Ferstl P, Trebicka J. Acute decompensation and acute-on-chronic liver failure[J]. Clin Liver Dis,2021,25(2):419-430.
[11] Jalan R, D'Amico G, Trebicka J, et al. New clinical and pathophysiological perspectives defining the trajectory of cirrhosis[J]. J Hepatol,2021,75(Suppl 1):S14-S26.
[12] Yoo H W, Park J W, Jung M J, et al. The prediction of liver decompensation using hepatic collagen deposition assessed by computer-assisted image analysis with Masson's trichrome stain[J]. Scand J Gastroenterol,2024, 59(1):85-91.
[13] Lehmann J, Praktiknjo M, Nielsen M J, et al. Collagen type Ⅳ remodelling gender-specifically predicts mortality in decompensated cirrhosis[J]. Liver Int,2019,39(5):885-893.
[14] Kerbert A J C, Gupta S, Alabsawy E, et al. Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure[J]. JHEP Rep,2021,3(6):100355.
[15] Al Kaabi H, Al Alawi A M, Al Falahi Z, et al. Clinical characteristics, etiology, and prognostic scores in patients with acute decompensated liver cirrhosis[J]. J Clin Med,2023,12(17):5756.
[16] Wang T, Tan W, Wang X, et al. Role of precipitants in transition of acute decompensation to acute-on-chronic liver failure in patients with HBV-related cirrhosis[J]. JHEP Rep,2022,4(10):100529.
[17] Li B, Hong C, Fan Z, et al. Prognostic and therapeutic significance of microbial cell-free DNA in plasma of people with acute decompensation of cirrhosis[J]. J Hepatol,2023,78(2):322-332.
[18] Simbrunner B, Villesen I F, Königshofer P, et al. Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease[J]. Liver Int,2022,42(11):2501-2512.
[19] Garbuzenko D V. Therapeutic possibilities of gut microbiota modulation in acute decompensation of liver cirrhosis[J]. World J Hepatol,2023,15(4):525-537.
[20] Trebicka J, Amoros A, Pitarch C, et al. Addressing profiles of systemic inflammation across the different clinical phenotypes of acutely decompensated cirrhosis[J]. Front Immunol,2019,10:476.
[21] Trebicka J, Macnaughtan J, Schnabl B, et al. The microbiota in cirrhosis and its role in hepatic decompensation[J]. J Hepatol,2021,75(Suppl 1):S67-S81.
[22] Engelmann C, Clària J, Szabo G, et al. Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction[J]. J Hepatol,2021,75(Suppl 1):S49-S66.
[23] Caraceni P, Vargas V, Solà E, et al. The use of rifaximin in patients with cirrhosis[J]. Hepatology,2021,74(3):1660-1673.
[24] Kronborg T M, Ytting H, Hobolth L, et al. Novel anti-inflammatory treatments in cirrhosis. A literature-based study[J]. Front Med (Lausanne),2021,8:718896.
[25] Jachs M, Hartl L, Schaufler D, et al. Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes[J]. Gut,2021,70(9):1758-1767.
[26] Königshofer P, Hofer B S, Brusilovskaya K, et al. Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies[J]. Hepatology,2022,75(3):610-622.
[27] Berzigotti A, Albillos A, Villanueva C, et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the sport diet study[J]. Hepatology,2017,65(4):1293-1305.
[28] Mendoza Y P, Rodrigues S G, Bosch J, et al. Effect of poorly absorbable antibiotics on hepatic venous pressure gradient in cirrhosis: a systematic review and meta-analysis[J]. Dig Liver Dis,2020,52(9):958-965.
[29] Zaccherini G, Aguilar F, Caraceni P, et al. Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF[J]. J Hepatol,2021,74(5):1117-1131.
[30] Casulleras M, Flores-Costa R, Duran-Güell M, et al. Albumin lipidomics reveals meaningful compositional changes in advanced cirrhosis and its potential to promote inflammation resolution[J]. Hepatol Commun,2022,6(6):1443-1456.
[31] Sorribas M, Jakob M O, Yilmaz B, et al. FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis[J]. J Hepatol,2019,71(6):1126-1140.
[32] Casulleras M, Zhang I W, López-Vicario C, et al. Systemic inflammation and immunopathology in acute-on-chronic liver failure[J]. Cells,2020,9(12):2632.
[33] Bernsmeier C, van der Merwe S, Périanin A. Innate immune cells in cirrhosis[J]. J Hepatol,2020,73(1):186-201.
[34] Prakash V, Arora V, Jindal A, et al. Combination of GM CSF and carbapenem is superior to carbapenem monotherapy in difficult-to-treat spontaneous bacterial peritonitis: a randomized controlled trial[J]. Liver Int,2023,43(6):1298-1306.
[35] Rathi S, Hussaini T, Yoshida E M. Granulocyte colony stimulating factor: a potential therapeutic rescue in severe alcoholic hepatitis and decompensated cirrhosis[J]. Ann Hepatol,2021,20:100211.
[36] Venkitaraman A, De A, Verma N, et al. Multiple cycles of granulocyte colony-stimulating factor in decompensated cirrhosis: a double-blind RCT[J]. Hepatol Int,2022,16(5):1127-1136. |
